Published in J Exp Med on October 01, 1982
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest (1988) 2.38
Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun (1988) 1.97
Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck. J Clin Invest (1992) 1.50
Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun (1997) 1.37
Molecular basis for serum resistance in Neisseria gonorrhoeae. Clin Microbiol Rev (1989) 1.32
Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin Microbiol Rev (1989) 1.29
The capsular polysaccharide is a major determinant of serum resistance in K-1-positive blood culture isolates of Escherichia coli. Infect Immun (1990) 1.24
Membrane changes induced by exposure of Escherichia coli to human serum. Infect Immun (1983) 1.12
Gonococcal infection in a nonhuman host is determined by human complement C1q. Infect Immun (1995) 1.06
Pelvic inflammatory disease isolates of Neisseria gonorrhoeae are distinguished by C1q-dependent virulence for newborn rats and by the sac-4 region. Infect Immun (1997) 1.03
A recombinant molecule from a disseminating strain of Neisseria gonorrhoeae that confers serum bactericidal resistance. Infect Immun (1987) 1.01
Lysis of complement-sensitive Entamoeba histolytica by activated terminal complement components. Initiation of complement activation by an extracellular neutral cysteine proteinase. J Clin Invest (1990) 0.93
Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity. Infect Immun (2002) 0.91
Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components. J Exp Med (1989) 0.90
Systemic gonococcal infection. Genitourin Med (1996) 0.89
Resistance of Escherichia coli to osmotically introduced complement component C9. Infect Immun (1991) 0.80
Experimental transmission of Neisseria gonorrhoeae from pregnant rat to fetus. Infect Immun (1999) 0.80
Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen. J Clin Invest (1989) 0.78
C9-mediated killing of bacterial cells by transferred C5b-8 complexes: transferred C5b-9 complexes are nonbactericidal. Infect Immun (1994) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION. J Bacteriol (1963) 45.03
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun (1978) 32.33
Studies on gonococcus infection. I. Pili and zones of adhesion: their relation to gonococcal growth patterns. J Exp Med (1971) 14.84
Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera. J Clin Invest (1976) 5.54
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Gonococci in urethral exudates possess a virulence factor lost on subculture. Nature (1970) 3.19
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
The serum bactericidal system: ultrastructural changes in Neisseria meningitidis exposed to normal rat serum. J Exp Med (1969) 2.32
STUDIES OF GONOCOCCAL INFECTION. II. THE BACTERIOLYTIC POWER OF THE WHOLE DEFIBRINATED BLOOD OF PATIENTS WITH GONOCOCCAL ARTHRITIS. J Clin Invest (1937) 2.18
Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol (1975) 2.15
Influence of colony type on susceptibility of gonococci to killing by human serum. J Immunol (1976) 2.14
Penicillin sensitivity and serum resistance are independent attributes of strains of Neisseria gonorrhoeae causing disseminated gonococcal infection. Infect Immun (1977) 2.09
The ninth component of human complement: purification and physicochemical characterization. J Immunol (1980) 2.09
How complement kills E. coli. I. Location of the lethal lesion. J Immunol (1981) 1.74
Role of blocking antibody in disseminated gonococcal infection. J Immunol (1978) 1.58
Natural serum bactericidal activity against Neisseria gonorrhoeae isolates from disseminated, locally invasive, and uncomplicated disease. J Immunol (1980) 1.52
How complement kills E. coli. II. The apparent two-hit nature of the lethal event. J Immunol (1981) 1.48
Structural similarities between C6 and C7 of human complement. J Immunol (1979) 1.41
The role of C9 in complement-mediated killing of Neisseria. J Immunol (1981) 1.35
Clinical manifestations of disseminated infection caused by Neisseria gonorrhoeae are linked to differences in bactericidal reactivity of infecting strains. Ann Intern Med (1981) 1.31
Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection. Clin Exp Immunol (1975) 1.18
The first complement component: evidence for an equilibrium between C1s free in serum and C1s bound in the C1 complex. J Immunol (1977) 0.95
Studies on the bactericidal reaction. II. Inhibition by antibody, and antibody requirements of the reaction. J Immunol (1953) 0.91
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum (1986) 6.11
A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science (2000) 5.78
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci U S A (1985) 3.31
Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet (1995) 3.29
IgA production without mu or delta chain expression in developing B cells. Nat Immunol (2001) 3.26
Bacteroides penicillinase. J Bacteriol (1968) 3.10
Cytolytic T cell granules. Isolation, structural, biochemical, and functional characterization. J Exp Med (1984) 2.86
Cytolysis by H-2-specific T killer cells. Assembly of tubular complexes on target membranes. J Exp Med (1983) 2.78
Assembly of two types of tubules with putative cytolytic function by cloned natural killer cells. Nature (1983) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Structure and function of human perforin. Nature (1988) 2.47
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell (1986) 2.38
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Rapid identification of Candida albicans septicemia in man by gas-liquid chromatography. J Clin Invest (1974) 2.29
Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci U S A (1985) 2.26
The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities. Science (1986) 2.21
Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med (1983) 2.18
Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol (1973) 2.18
Influence of colony type on susceptibility of gonococci to killing by human serum. J Immunol (1976) 2.14
Radiating leg pain in the older patient. Hosp Pract (Off Ed) (1991) 2.03
Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol (1976) 2.02
Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci U S A (1984) 2.01
Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci U S A (1982) 1.96
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med (1982) 1.92
Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol (1987) 1.92
The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol (1978) 1.81
Prevalence of congenital or acquired complement deficiency in patients with sporadic meningocococcal disease. N Engl J Med (1983) 1.79
Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci U S A (1979) 1.76
Anaerobic infection of the paranasal sinuses. N Engl J Med (1974) 1.76
Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol (1978) 1.76
The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med (1996) 1.72
Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem (1982) 1.70
Killing of Aspergillus spores depends on the anatomical source of the macrophage. Infect Immun (1983) 1.68
Role of magnesium in the enzyme-linked immunosorbent assay for lipopolysaccharides of rough Escherichia coli strain J5 and Neisseria gonorrhoeae. J Infect Dis (1980) 1.64
C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J Immunol (1979) 1.63
Passive immunization against the local Shwartzman reaction. J Immunol (1972) 1.62
Analysis of sugars in bacterial endotoxins by gas-liquid chromatography. Anal Biochem (1969) 1.60
Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest (1982) 1.59
Role of blocking antibody in disseminated gonococcal infection. J Immunol (1978) 1.58
Simple method for culturing anaerobes. Appl Microbiol (1973) 1.58
Protection against lethality of E. coli endotoxin with "O" antiserum. Ann N Y Acad Sci (1966) 1.57
C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med (1979) 1.55
Cytolysis by Ca-permeable transmembrane channels. Pore formation causes extensive DNA degradation and cell lysis. J Exp Med (1989) 1.54
Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis (1977) 1.54
Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci U S A (1993) 1.51
Cloning, analysis, and expression of murine perforin 1 cDNA, a component of cytolytic T-cell granules with homology to complement component C9. Proc Natl Acad Sci U S A (1989) 1.50
G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol (1997) 1.49
Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry (1985) 1.48
Functional channel formation associated with cytotoxic T-cell granules. Proc Natl Acad Sci U S A (1986) 1.43
Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med (1978) 1.42
Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis. Proc Natl Acad Sci U S A (1979) 1.41
Structural similarities between C6 and C7 of human complement. J Immunol (1979) 1.41
Membrane attack by complement. Mol Immunol (1984) 1.39
Immobilizing antibodies in urine. II. Prevention of ascending spread of Proteus mirabilis. Invest Urol (1974) 1.39
Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia. Mayo Clin Proc (1996) 1.38
Activation of the classical pathway of complement by rheumatoid factors. Assessment by radioimmunoassay for C4. Arthritis Rheum (1982) 1.37
The role of C9 in complement-mediated killing of Neisseria. J Immunol (1981) 1.35
The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol (1977) 1.35
Antigenic variation in Giardia lamblia: cellular and humoral immune response in a mouse model. Parasite Immunol (1990) 1.35
Characterization of three serine esterases isolated from human IL-2 activated killer cells. J Immunol (1988) 1.33
Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol (1997) 1.33
Potassium iodide sensitivity in four patients with hypocomplementemic vasculitis. Ann Intern Med (1979) 1.32
Differentiation of neisseriaceae by isoenzyme electrophoresis. J Infect Dis (1983) 1.32
Correlation between thermal death and membrane fluidity in Bacillus stearothermophilus. Proc Natl Acad Sci U S A (1974) 1.32
Treatment and prevention of intravascular coagulation with antiserum to endotoxin. J Infect Dis (1973) 1.32
Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl (1984) 1.32
In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest (1986) 1.31
A plaque assay on agar for detection of gram-negative bacilli sensitive to complement. J Immunol (1972) 1.30
Ultrastructure of the membrane attack complex of complement: detection of the tetramolecular C9-polymerizing complex C5b-8. Proc Natl Acad Sci U S A (1982) 1.30
Immunization against retrograde pyelonephritis. I. Production of an experimental model of severe ascending Escherichia coli pyelonephritis without bacteremia in rats. Am J Pathol (1974) 1.30
Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J Immunol (1999) 1.29
Intracranial suppurative disease. Early presumptive diagnosis and successful treatment without surgery. JAMA (1971) 1.29
Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol (1999) 1.29
Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol (1997) 1.29
The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. J Immunol (1981) 1.29
Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences. J Immunol (1980) 1.27
Properties of a purified pore-forming protein (perforin 1) isolated from H-2-restricted cytotoxic T cell granules. J Exp Med (1986) 1.27
Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum. Trans Assoc Am Physicians (1975) 1.26
Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut (2002) 1.25
Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum (1984) 1.25
The C5b-6 complex: reaction with C7, C8, C9. J Immunol (1978) 1.25
SC5b-9 complex of complement: formation of the dimeric membrane attack complex by removal of S-protein. J Immunol (1980) 1.25
Structure of the human perforin gene. A simple gene organization with interesting potential regulatory sequences. J Immunol (1989) 1.24
Detection of perforin and granzyme A mRNA in infiltrating cells during infection of mice with lymphocytic choriomeningitis virus. Eur J Immunol (1989) 1.24
A study of particle sizes, shapes and toxicities present in a boivin-type endotoxic preparation. Ann N Y Acad Sci (1966) 1.24
Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol (1996) 1.20
The Influence of Endotoxin on Resistance to Infection. Bull N Y Acad Med (1961) 1.20
Structure and expression of murine CD30 and its role in cytokine production. J Immunol (1996) 1.20